Z-Ligustilide: A Potential Therapeutic Agent for Atherosclerosis Complicating Cerebrovascular Disease

Biomolecules. 2024 Dec 18;14(12):1623. doi: 10.3390/biom14121623.

Abstract

Atherosclerosis (AS) is one of the major catalysts of ischemic cerebrovascular disease, and the death and disease burden from AS and its cerebrovascular complications are increasing. Z-ligustilide (Z-LIG) is a key active ingredient in Angelica sinensis (Oliv.) Diels and Ligusticum chuanxiong Hort. In this paper, we first introduced LIG's physicochemical properties and pharmacokinetics. Then, we reviewed Z-LIG's intervention and therapeutic mechanisms on AS and its cerebrovascular complications. The mechanisms of Z-LIG intervention in AS include improving lipid metabolism, antioxidant and anti-inflammatory effects, protecting vascular endothelium, and inhibiting vascular endothelial fibrosis, pathological thickening, and plaque calcification. In ischemic cerebrovascular diseases complicated by AS, Z-LIG exerts practical neuroprotective effects in ischemic stroke (IS), transient ischemic attack (TIA), and vascular dementia (VaD) through anti-neuroinflammatory, anti-oxidation, anti-neuronal apoptosis, protection of the blood-brain barrier, promotion of mitochondrial division and angiogenesis, improvement of cholinergic activity, inhibition of astrocyte proliferation, and endoplasmic reticulum stress. This paper aims to provide a basis for subsequent studies of Z-LIG in the prevention and treatment of AS and its cerebrovascular complications and, thus, to promote the development of interventional drugs for AS.

Keywords: Z-ligustilide; atherosclerosis; intracranial atherosclerotic disease; ischemic cerebrovascular disease; ischemic stroke; transient ischemic attack; vascular dementia.

Publication types

  • Review

MeSH terms

  • 4-Butyrolactone* / analogs & derivatives
  • 4-Butyrolactone* / chemistry
  • 4-Butyrolactone* / pharmacology
  • 4-Butyrolactone* / therapeutic use
  • Animals
  • Anti-Inflammatory Agents / chemistry
  • Anti-Inflammatory Agents / pharmacology
  • Anti-Inflammatory Agents / therapeutic use
  • Antioxidants / chemistry
  • Antioxidants / pharmacology
  • Antioxidants / therapeutic use
  • Atherosclerosis* / drug therapy
  • Atherosclerosis* / metabolism
  • Cerebrovascular Disorders* / drug therapy
  • Humans
  • Neuroprotective Agents / chemistry
  • Neuroprotective Agents / pharmacology
  • Neuroprotective Agents / therapeutic use

Substances

  • ligustilide
  • 4-Butyrolactone
  • Neuroprotective Agents
  • Antioxidants
  • Anti-Inflammatory Agents